Vasculearn Network
May 16, 2026, 16:04
How We Assess Coagulation in Patients on FXa Inhibitors and What May Come Next – Vasculearn Network
Vasculearn Network shared a post on X:
“New episode of Clot, Clot, Who’s There?
In urgent bleeding, PT/aPTT and anti-Xa are often the default.
But are they the right signal?
Our latest episode challenges how we assess coagulation in patients on FXa inhibitors, and what may come next.”
Stay updated with Hemostasis Today.
-
Oct 6, 2026, 10:56Moustafa Abdou: LE Cells and the Early Diagnosis of Lupus
-
Oct 6, 2026, 10:35Caitlin Raymond: Understanding IgA Deficiency and Anaphylaxis Risk
-
Oct 6, 2026, 10:15Zeeshan Ali Baig: AI-Designed Peptide for Rare Bleeding Disorder
-
Oct 6, 2026, 10:12Srivatsan Rangachari: Stem Cell Transplant for 12-Year-Old with Fanconi Anaemia
-
Oct 6, 2026, 09:56Anitha Narayanamurthy: A Possible Missing Link in Unexplained Blood Test Abnormalities
-
Oct 6, 2026, 09:46Francois Roubille: Biomarkers and Long-Term Prognosis After Revascularised STEMI
-
Oct 6, 2026, 09:20EAS Rare Lipid Disorder Course – Advancing Lipid Disorder Education – European Atherosclerosis Society
-
Oct 6, 2026, 09:12Fionnuala Ní Áinle: Lisa Ryan’s First Thrombocalc VTE Research Report
-
Oct 6, 2026, 09:02David McIntosh: Preventable Maternal and Newborn Deaths – The Urgent Need for Action